论文部分内容阅读
目的:通过探讨血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体拮抗剂联合使用在治疗糖尿病肾病的不良反应,旨在为临床合理用药提供理论依据。方法:选择2010年1月-2014年1月在我院接受治疗的糖尿病肾病患者96例,随机平均分成对照组1、对照组2和研究组,分别给予血管紧张素转换酶抑制剂、血管紧张素Ⅱ受体拮抗剂及两种药物联合使用治疗糖尿病肾病,统计两组患者不良反应发生率及发生症状。结果:研究组不良反应发生率为9.375%、对照组Ⅰ为28.125%、对照组Ⅱ为12.50%,研究组与对照组Ⅱ差异不显著,但与对照组Ⅰ差异显著,且P<0.05差异有统计学意义。结论:血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体拮抗剂联合使用治疗糖尿病肾病不良反应较单独使用低,是一种安全高效的治疗方式。
Objective: To investigate the adverse effects of angiotensin converting enzyme inhibitor and angiotensin Ⅱ receptor antagonist in the treatment of diabetic nephropathy, and to provide a theoretical basis for clinical rational drug use. Methods: A total of 96 patients with diabetic nephropathy treated in our hospital from January 2010 to January 2014 were randomly divided into control group 1, control group 2 and study group. Angiotensin converting enzyme inhibitors Ⅱ receptor antagonists and two drugs used in combination treatment of diabetic nephropathy, the incidence of adverse reactions and the occurrence of symptoms in both groups were statistically analyzed. Results: The incidence of adverse reactions was 9.375% in the study group, 28.125% in the control group and 12.50% in the control group Ⅱ. There was no significant difference between the study group and the control group Ⅱ, but significant difference with the control group Ⅰ, P <0.05 difference had Statistical significance. Conclusion: The combination of angiotensin converting enzyme inhibitor and angiotensin Ⅱ receptor antagonist is a safe and effective treatment for patients with diabetic nephropathy.